Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | ACE | P12821 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12860606 | 0.90 | HSD11B1 (0.44) | HSD11B1CYP3A4CYP2C9CYP2C19ACE | |
| SCHEMBL14144468 | 0.87 | HSD11B1 (0.43) | HSD11B1CYP3A4CYP2C9CYP2C19ACE | |
| SCHEMBL8038056 | 0.84 | HSD11B1 (0.40) | HSD11B1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8038060 | 0.82 | HSD11B1 (0.51) | HSD11B1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4298912 | 0.80 | HSD11B1 (0.45) | HSD11B1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4100291 | 0.80 | HSD11B1 (0.45) | HSD11B1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4304050 | 0.80 | HSD11B1 (0.45) | HSD11B1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4294143 | 0.80 | HSD11B1 (0.45) | HSD11B1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4296589 | 0.79 | HSD11B1 (0.46) | HSD11B1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL28775897 | 0.79 | HSD11B1 (0.46) | HSD11B1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION | 2011-02-03 | — | — | US | disclosed |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION | 2011-02-03 | — | — | US | disclosed |
| WO-2009108766-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER ' S DISEASE | SCHERING CORPORATION (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN1 | HSD11B1 653/4885CYP3A4 3531/4885CYP2C9 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.